Video: Vanquish core video infographic
The Vanquish Core is a powerful system designed for dependability whilst giving you exceptional results in an intuitive and easy to use instrument.
List view / Grid view
The Vanquish Core is a powerful system designed for dependability whilst giving you exceptional results in an intuitive and easy to use instrument.
The EDQM and European Pharmacopoeia have decided to share Ph. Eur. quality standards for COVID-19 vaccine developers to support their research.
Separate your science from the status quo, advanced solutions offering superior retention time stability, flexible integration and minimal maintenance.
Charged aerosol detection is a technique capable of measuring any non-volatile and many semi-volatile species in a pharmaceutical applications.
The investigational SARS-CoV-2 vaccine developed by J&J is now due to start its Phase I/IIa clinical trial at the end of July.
Coating the tetanus portion of the DTP vaccine in silica rendered it thermally stable up to 100°C and able to be distributed without refrigeration.
Tim Wilsdon and Ryan Lawlor from Charles River Associates explain why price-based procurement strategies can limit the long-term effectiveness and sustainability of vaccine programmes.
This application note shows the neutralisation efficiency of ICR swabs for sanitsed surfaces in aseptic manufacturing environments.
The vaccine alliance said the Covax AMC programme is the first in a series of financing programmes to ensure low- and middle-income countries will have access to COVID-19 vaccines.
This application note shows the detection of low numbers of different bacterial test strains from Neoprene® gloves.
The company announces it has been task ordered by BARDA to assist in the US government’s efforts to deliver COVID-19 vaccines.
Advent announced it has manufactured and delivered the first 4,000 doses of the AZD1222 vaccine candidate for the University of Oxford clinical trial.
The research will identify sources of data to monitor coverage and effectiveness, and support pharmacovigilance of COVID-19 vaccines once they are approved.
The adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine candidate safely induced T cell and antibody responses in 108 adults.
Dr Saurabh Kumar Banerjee outlines the impact of COVID-19 on immunisation programmes in India and how organisations can hope to mitigate the consequences of missed vaccine doses.